Business, Technology

NICE Actimize honored for AI and advanced analytics innovation in Holistic Trade Surveillance by Regulation Asia

NICE Actimize receives Regulation Asia’s Excellence Award for innovation in artificial intelligence and analytics to spot market abuse, conduct risk and suspicious communications HOBOKEN, N.J. — (BUSINESS WIRE) — NICE Actimize, a NICE (Nasdaq: NICE) business, announced today that its Holistic Trade and

Business, Health Care

European Commission approves KEYTRUDA® (pembrolizumab) as first-line treatment in adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer

KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy KENILWORTH, N.J. — (BUSINESS